BPI-572270

BPI-572270 is an investigational, orally bioavailable small molecule inhibitor developed by Betta Pharmaceuticals that specifically targets the KRAS G12D mutation. KRAS G12D is a frequent driver mutation in several aggressive cancers, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). By selectively binding to the KRAS G12D protein, BPI-572270 inhibits the constitutive activation of the RAS signaling pathway, thereby blocking downstream cascades like RAF-MEK-ERK that are essential for tumor cell proliferation and survival. The drug is currently being evaluated in Phase 1/2 clinical trials to determine its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors harboring the KRAS G12D mutation.